Penicillins as β-lactamase-dependent prodrugs: Enabling role of a vinyl ester exocyclic to the lactam ring

Chemical Communications

Volumn , Issue 20, 2004, Pages 2332-2333

  Ruddle, Carol C ^a   Smyth, Timothy P ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; BETA LACTAMASE; ESTER; PENICILLIN DERIVATIVE; PRODRUG; VINYL DERIVATIVE;

ARTICLE; CATALYSIS; DRUG HYDROLYSIS; DRUG STRUCTURE; PH; STRUCTURE ACTIVITY RELATION;

EID: 8644249388     PISSN: 13597345     EISSN: None     Source Type: Journal    
DOI: 10.1039/b409517k     Document Type: Article

References (18)

1. (a) T. P. Smyth, M. E. O'Donnell, M. J. O'Connor and J. O. St Ledger, Tetrahedron, 2000, 56, 5699-5707;
2. (b) T. P. Smyth, M. E. O'Donnell, M. J. O'Connor and J. O. St Ledger, J. Org. Chem., 1998, 63, 7600-7618;
3. (c) T. P. Smyth, M. J. O'Connor and M. E. O'Donnell, J. Org. Chem., 1999, 64, 3132-3138.
4. (a) J. D. Buynak, A. S. Rao and S. D. Nidamarthy, Tetrahedron Lett., 1998, 39, 4945-4946;
5. (b) J. D. Buynak, Patent number WO 99/33837, 1999;
6. (c) J. D. Buynak, K. Wu, B. Bachmann, D. Khasnis, L. Hua, H. K. Nguyen and C. L. Carver, J. Med Chem., 1995, 38, 1022-1034;
7. (d) J. D. Buynak, V. R. Doppalapudi and G. Adam, Bioorg. Med. Chem. Lett., 2000, 10, 853-857.
8. -1 more stable than its isomeric form C.
9. In the case of B1, steric hindrance by the t-butyl group blocks addition of the nucleophile to the ester carbonyl, which is the rate-determining step.
10. A parallel for this is found in the intramolecular nucleophilic addition that occurs within the β-lactam-ring-cleaved structure derived from 6(Z)-acetylmethylenepenicillanic acid (a potent β-lactamase inhibitor): M. Arisawa and S. Adam, Biochem. J., 1983, 211, 447-454.
11. 6(Z)-t-butoxycarbonylmethylenepenicillanate and 6(Z)- methoxycarbonylmethylenepenicillanate have been found to be β-lactamase substrates (the corresponding sulfones are inhibitors), however, the fate of the β-lactam-ring-cleaved structures was not reported on: (a) J. D. Buynak, B. Geng, B. Bachmann and L. Hua, Bioorg. Med. Chem. Lett., 1995, 5, 1513-1518;
12. (b) D. Habich and K. Metzger, Heterocycles, 1986, 24, 289-296.
13. J. Marchand-Brynaert, H. Vanlierde and L. Ghosez, Bull. Soc. Chim. Belg., 1988, 97, 1081-1093.
14. Q. Li, J. Y. Lee, R. Castillo, M. S. Hixon, C. Pujol, V. R. Doppalapudi, H. M. Shepard, G. M. Wahl, T. J. Lobl and M. F. Chan, Antimicrob. Agents Chemother., 2002, 46, 1262-1268.
15. (a) H. P. Svensson, I. S. Frank, K. K. Berry and P. D. Senter, J. Med. Chem., 1998, 41, 1507-1512 and references therein;
16. (b) T. W. Hudyma, K. Bush, K. L. Colson, R. A. Firestone and H. D. King, Bioorg. Med. Chem. Lett., 1993, 3, 323-328.
17. A. Awada, C. J. A. Punt, M. J. Piccart, O. van Tellingen, L. van Manen, J. Kerger, Y. Groot, J. Wanders, J. Verweij and D. J. Wagener, Br. J. Cancer, 1999, 79, 1454-1461 and references therein.
18. W. Gao, B. Xing, R. Y. Tsien and J. Rao, J. Am. Chem. Soc., 2003, 125, 11146-11147 and references therein.